TIDMLID
LiDCO Group Plc
08 September 2016
LiDCO Group Plc
("LiDCO" or the "Company")
LiDCO's technology shown to improve outcomes in surgery
LiDCO (AIM: LID), the hemodynamic monitoring company, welcomes
the recent publication of four studies that provide further
evidence of the improved outcome benefits derived from the use of
LiDCOrapid in high volume general and cardiac surgery.
The Society of Critical Care Medicine journal has published a
study evaluating the effects of goal directed therapy using
LiDCOrapid in high-risk patients undergoing cardiac surgery. The
randomised controlled trial involved 126 patients undergoing
coronary artery bypass surgery or valve repair. The authors
concluded that using LiDCOrapid in these high-risk patients for
implementing a goal-directed hemodynamic therapy decreased major
complications and also reduced ICU and hospital length of stay. The
incidence of infection was reduced by 57% and the frequency of low
cardiac output syndrome was reduced by 76%. This group stayed in
hospital on average three days less than the standard treatment
group. This is an important study, high-risk cardiac patients
require hemodynamic and fluid management both in surgery and also
post operatively in the ICU. Historically this has only been
possible through using a highly invasive pulmonary artery catheter.
The LiDCOrapid's minimal and non-invasive nature provides advanced
monitoring while avoiding additional invasive catheter
insertion.
The World Journal of Surgery recently published a large study
examining the influence of an enhanced recovery programme using
LiDCOrapid for the fluid management element on the outcomes of
upper gastrointestinal cancer surgery in 252 patients. Oesophageal
cancer surgery is frequently performed in malnourished patients who
go on to have a higher incidence of surgical complications that
impede recovery. Both overall length of hospital stay and critical
care length of stay were significantly shorter. Patients in the
enhanced recovery group, where LiDCO technology was used, left
hospital on average three days earlier.
Presented at the 11(th) Annual Academic Surgical Congress in the
USA early this year and now having been peer-reviewed and
published, a 394 patient study from a major hospital in the USA
showed that implementing an enhanced recovery programme for
elective abdominal surgery using intraoperative fluid management
guided by LiDCOrapid resulted in a statistically significant
decrease of two days in mean length of stay. In addition, the
enhanced recovery group had a zero mortality rate compared to a
2.6% mortality rate in the standard care group. The authors also
noted that the cost of surgery was less in the enhanced recovery
group.
Finally in another of our key growth markets, China, a
randomised control trial has been published assessing the
application of LiDCOrapid for peri-operative fluid therapy for
elderly patients undergoing total hip replacement under combined
spinal-epidural anesthesia. Hemodynamic changes are relatively
severe in these patients and usu-ally include incidences of low
blood pressure and reduced organ perfusion that causes ischemia and
complications. Clearly an optimal fluid management protocol is
crucial for these patients in order to decrease the incidence of
hypotension. Use of the LiDCOrapid to implement a simple fluid
management protocol reduced the number of times pharmaceutical
interventions were required while maintaining improved blood
pressure, with the result that complications were significantly
lower in the LiDCOrapid fluid managed group.
Commenting, Matt Sassone, Chief Executive Officer of LiDCO,
said: "We continue to see a wealth of clinical evidence
demonstrating the benefit of using LiDCO technology in multiple
different high-risk surgery procedures from around the world.
Having peer-reviewed journal published data substantiating the
clinical effectiveness of LiDCOrapid in an expanding number of
large volume surgical indications will help us as we seek to
further commercialise the business."
Papers Referenced:
Eduardo A. Osawa; Andrew Rhodes; Giovanni Landoni; Filomena R.
B. G. Galas; Julia T. Fukushima, et al. Effect of Perioperative
Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes
Following Cardiac Surgery: A
Randomized Clinical Trial and Systematic Review Crit Care Med. 2016 Apr; 44(4):724-33. doi: 10.1097/CCM.0000000000001479
A. Karran, J. Wheat, D. Chan, P. Blake, R. Barlow, W. G. Lewis.
Propensity Score Analysis of an Enhanced Recovery Programme in
Upper Gastrointestinal Cancer Surgery. World J Surg (2016)
40:1645-1654. DOI 10.1007/s00268-016-3473-6
Fitzgerald T, Mosquera C, Koutlas N, Vohra N, Lee K, Zervos E.
Enhanced recovery after surgery in a single high-volume surgical
oncology unit: Details matter. Surgery Research and Practice Volume
2016 (2016), Article ID 6830260
Guang Han, Kun Liu, Hang Xue, Ping Zhao. Application of
LiDCO-Rapid in peri-operative fluid therapy for aged patients
undergoing total hip replacement. Int J Clin Exp Med
2016;9(2):4473-4478, www.ijcem.com /ISSN:1940-5901/IJCEM0010819
For further information, please contact:
LiDCO Group Plc www.lidco.com
Matt Sassone (CEO) Tel: +44 (0)20 7749 1500
Paul Clifford (Finance Director)
finnCap Tel: +44 (0)20 7600 1658
Geoff Nash / Emily Watts (Corporate Finance)
Stephen Norcross (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or lidco@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Lianne Cawthorne Mob: 07584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive
hemodynamic equipment to hospitals used to monitor the amount of
blood flowing around the body and ensure that vital organs are
adequately oxygenated. LiDCO's products facilitate the application
of hemodynamic optimisation protocols for high risk patients in
both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation
of patients' hemodynamic status in high risk patients produces
better outcomes and reduced hospital stay. LiDCO's computer-based
technology, developed at St Thomas' Hospital in London, has been
shown to significantly reduce morbidity and complications, length
of stay and overall costs associated with major surgery.
Key Products:
LiDCOunity: a hemodynamic monitor that combines the full suite
of LiDCO technology (non-invasive, minimally invasive and
calibrated technologies) into one platform. Designed to have the
flexibility to adapt to a patient's changing acuity, the product
enables clinicians to seamlessly transition between non-invasive,
minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus: a computer-based platform monitor used in the
Intensive Care Unit for real-time continuous display of hemodynamic
parameters including cardiac output, oxygen delivery and
fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid: a cardiac output monitor designed specifically for
use in the operating theatre for fluid and drug management. The
monitor enables anaesthetists to receive accurate and immediate
feedback on the patient's fluid and hemodynamic status - a key
measure of overall well-being before, during and after surgery. The
LiDCOrapid provides:
-- early and rapid warning of hemodynamic change to aid choice
of therapeutic route: fluid or drug
-- quantification of hemodynamic response guidance on effective
delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid
monitor to co-display Medtronic's level of consciousness parameter
('BIS(TM') )* and add the convenience of CNSystem's continuous
non-invasive blood pressure monitoring ('CNAP')**. This addresses a
growing requirement for non-invasive monitoring solutions that are
more comprehensive and can effectively replace multiple single
parameter monitors.
LiDCOview: an easy-to-use graphical display of historical
LiDCOplus and LiDCOrapid hemodynamic data.
*BIS(TM) and Bispectral Index are trademarks of Medtronic
registered in the US and foreign countries.
**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or
smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through
a network of specialty critical care and anaesthesia distributors
in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on
AIM.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFVEARIDIIR
(END) Dow Jones Newswires
September 08, 2016 02:01 ET (06:01 GMT)
Lidco (LSE:LID)
Historical Stock Chart
From Apr 2024 to May 2024
Lidco (LSE:LID)
Historical Stock Chart
From May 2023 to May 2024